Navigation Links
Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
Date:7/8/2011

asis.  The Company has two broad platform technologies:  dendritic cell-based vaccines and certain therapeutic antibodies.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal form of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  The Company's second technology platform, involving antibodies to CXCR4, is at the pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-L and future clinical trials, are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factor
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. James Bond Meets Cheaper by the Dozen: An Action Thriller the Entire Family Will Enjoy
2. Nobel Spotlight on IVF Boosts Family Building Procedures
3. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
4. Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year
5. Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems
6. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
7. DNA 11 Unveils Modern-Day Family Portraits at The Museum of Science and Industry's Smart Home: Green + WIRED Exhibit
8. DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors
9. Family Medicine Cabinet: Free, New On-Line Tool Helps Track Your Medication Safety
10. GeneNews to exhibit ColonSentry(TM) at Family Medicine Forum 2008
11. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... which brings Q3 orders to $5.8 million and provides a good ... in North America and one in the ... bid new projects at record levels," said Peter Bruijns , ... at the end of Q3 than they have been for any ...
(Date:10/20/2014)... 20, 2014  GenVec, Inc. (NASDAQ: GNVC ) ... Ph.D., from its board of directors effective on October 24, ... and served as its chairman from June 2006 to November ... and Corporate Governance and Audit Committees of the board.  ... decade of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... AngioGenex, Inc. (OTC,Bulletin Board: AGGX), a New York-based ... drug development, announced that its,shareholders elected William Garland ... Meeting. The company also announced that the newly ... as its Chairman. As he,assumes this new post, ...
... Incorporated,(Nasdaq: VICL ) today announced that Vijay ... a panel discussion on biodefense and,pandemic influenza Wednesday ... Francisco, CA - January 7-10)., The session ... & Aldridge LLP.,Co-keynotes for the session are Rajeev ...
... CLEVELAND An interdisciplinary team from the department ... Reserve University, the Louis Stokes Cleveland VA Medical ... the December 2007 cover of Nature Nanotechnology, one ... research in nanoscience and nanotechnology., Jeffrey R. Capadona, ...
Cached Biology Technology:William Garland Joins AngioGenex's New Board of Directors 2William Garland Joins AngioGenex's New Board of Directors 3Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference 2
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/15/2014)... will be awarded the 44th Rosenstiel Award for Distinguished ... pioneering research exploring the mechanisms of genomic instability and ... Alt is the second alumnus to win the Rosenstiel ... in 2003. , Alt is the Charles A. Janeway ... Medical School and an investigator at the Howard Hughes ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... animal cell is like a small city, with factoriescalled ... life functions. A network of intercellular "highways," called microtubules, ... speedily about the cell to keep this vital machinery ... Proceedings of the National Academy of Sciences ...
... with the energy company Fortum, engineering company Metso and ... the cogeneration of heating energy and bio-oil in the ... based on combining pyrolysis and fluidised bed technology. Thanks ... expected to increase considerably in the next few decades. ...
... the genome and the products of its expression lie microRNAs, ... become stuff. In fact, many cancers use microRNA to magnify ... helpful genes that would otherwise suppress tumors. A University of ... the Journal of Biological Chemistry shows that in ...
Cached Biology News:Study sheds light on how cells transport materials along crowded intercellular 'highways' 2Study sheds light on how cells transport materials along crowded intercellular 'highways' 3VTT wins European innovation prize for a new bio-oil production technique 2MicroRNA-218 targets medulloblastoma, most aggressive childhood brain cancer 2
... is a G1 cyclin required for G1-phase ... a proto-oncogene. cyclin D2 can phosphorylate ... Species Reactivity: Human, Mouse, and Rat. ... is particularly well suited for neutralization of ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
... for 25 chips provides the chips and ... (at picogram levels) with the Experion automated ... HighSens microfluidic chips, 2 x 1,250 microliters ... HighSens stain, 20 microliters RNA ladder, 2 ...
Biology Products: